Alectinib is an organic heterotetracyclic compound, specifically 6,6-dimethyl-5,6-dihydro-11H-benzo[b]carbazol-11-one, with additional cyano, 4-(morpholin-4-yl)piperidin-1-yl, and ethyl substituents at positions 3, 8, and 9 respectively. It is used as the hydrochloride salt in the treatment of anaplastic lymphoma kinase-positive, metastatic non-small cell lung cancer. Alectinib functions as an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor and an antineoplastic agent. It belongs to the classes of organic heterotetracyclic compounds, morpholines, piperidines, nitriles, and aromatic ketones, and is the conjugate base of alectinib(1+).
